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Abstract: The mechanisms that drive formation of the HIV capsid, first as an immature particle
and then as a mature protein shell, remain incompletely understood. Recent discoveries of
positively-charged rings in the immature and mature protein hexamer subunits that comprise them
and their binding to the cellular metabolite inositol hexakisphosphate (IP6) have stimulated exciting
new hypotheses. In this paper, we discuss how data from multiple structural and biochemical
approaches are revealing potential roles for IP6 in the HIV-1 replication cycle from assembly
to uncoating.
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1. Introduction
The HIV structural protein Gag and its products are involved at multiple steps in the viral
replication cycle. The first step, assembly, takes place during the formation and budding of virus
particles from an infected cell. The multi-domain structural protein Gag (Figure 1A) polymerizes
into an immature lattice underneath and contacts the plasma membrane. During or after release of
the virus by budding, the viral protease PR then cleaves Gag into its constituent domains and leads
to a structural rearrangement called maturation. The liberated CA protein, which comprises two
separately folded sub-domains (CANTD and CACTD), forms a new lattice known as the mature capsid
that surrounds the RNA genome and associated proteins including reverse transcriptase (RT). Both the
immature (Gag) and the mature (CA) lattice are built of hexamers, but the molecular intra-hexamer
and inter-hexamer contacts differ. In addition, the mature CA lattice contains 12 pentamers that are
required to ensure that the lattice and resulting capsid are completely closed. The mature capsid is
deposited into the cytoplasm of a target cell following viral envelope fusion with the cell membrane.
There the capsid protects the virus from sensors and degradative enzymes, ensures efficient reverse
transcription of the viral genome from RNA to DNA, and facilitates transport through the cytosol
and into the nucleus. The precise interplay of these events is unclear but requires capsid interaction
with a number of host co-factor molecules. The final part of this step is uncoating, i.e. the partial or
complete dissolution of the capsid lattice. Exactly where, when, and how uncoating happens is hotly
debated, but it is likely more complex than the immediate and spontaneous collapse pictured in early
models. In this review, we will consider how the recently identified co-factor molecule IP6 impacts
these steps.
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Figure 1. Role of IP6 on immature and mature assembly. (A) Drawing of an immature virus particle 
budding from cellular plasma membrane. (B) Negative stain EM image of immature-like virus 
particles assembled in vitro with IP6. (C) Depiction of Gag molecule from (A) showing IP6 bound at 
the interface of CACTD and SP. (D) Drawing of a mature virus particle. Following cleavage of Gag, IP6 
promotes the formation of the mature lattice by CA. (E) Negative stain EM image of IP6-induced 
assembly of HIV-1 CA protein into mature-like virus particles. (F) Depiction of CA molecule from (D) 
with IP6 bound. (G) Top and side-view of IP6 d-myo-IP6, the most abundant isoform, with one axial 
and five equatorial phosphates. Note that in diagrams A and C, the viral envelope proteins and the 
RNA genome and associated proteins are not shown. 
2. Assembly 
As for most other retroviruses, HIV-1 Gag oligomerizes at the plasma membrane to create a 
curved lattice that makes up the protein shell of the immature virus particle [1]. The assembly 
properties of Gag have been studied extensively in vitro, starting some 20 years ago [2–4]. In this 
system, purified Gag protein or Gag truncation mutants are mixed with a nucleic acid, which is 
typically single-stranded DNA or RNA that interacts with the highly basic NC domain and, thus, 
brings protein molecules in close proximity. Under the right conditions, rapid, spontaneous assembly 
occurs, which results in the formation of spherical or tubular/conical virus-like particles (VLPs) 
closely resembling virus particles that have budded from cells. For HIV-1, immature assembly 
proceeds most favorably at slightly basic pH and physiological ionic strength. By contrast, the CA 
protein by itself and the CA-NC protein in the presence of nucleic acid assemble into the mature 
lattice, which is a reaction that is more efficient at a slightly acid pH. Purified CA protein, which does 
not require addition of nucleic acid, forms a mature lattice only at unphysiologically high salt such 
as 1 M NaCl. The products of CA and CA-NC assembly are mostly tubes, which are composed of 
hexamers, in addition to some closed core-like structures that are composed of hexamers and 12 
pentamers [4–6]. 
A truncated HIV-1 Gag protein missing most of the MA domain (delta 16–99) forms spherical 
particles with an immature lattice, which was shown over 15 years ago [7]. However, under the 
conditions used initially, full-length Gag, which contains an intact (but not myristoylated) MA 
domain, forms only aberrant small spherical particles in vitro [2]. This size defect could be corrected 
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2. Assembly
As for most other retroviruses, HIV-1 Gag oligomerizes at the plasma membrane to create a curved
lattice that makes up the protein shell of the immature virus particle [1]. The assembly properties of
Gag have been studied extensively in vitro, starting some 20 years ago [2–4]. In this system, purified
Gag protein or Gag truncation mutants are mixed with a nucleic acid, which is typically single-stranded
DNA or RNA that interacts with the highly basic NC domain and, thus, brings protein molecules in
close proximity. Under the right conditions, rapid, spontaneous assembly occurs, which results in the
formation of spherical or tubular/conical virus-like particles (VLPs) closely resembling virus particles
that have budded from cells. For HIV-1, immature assembly proceeds most favorably at slightly basic
pH and physiological ionic strength. By contrast, the CA protein by itself and the CA-NC protein in
the presence of nucleic acid assemble into the mature lattice, which is a reaction that is more efficient at
a slightly acid pH. Purified CA protein, which does not require addition of nucleic acid, forms a mature
lattice only at unphysiologically high salt such as 1 M NaCl. The products of CA and CA-NC assembly
are mostly tubes, which are composed of hexamers, in addition to some closed core-like structures that
are composed of hexamers and 12 pentamers [4–6].
A truncated HIV-1 Gag protein missing most of the MA domain (delta 16–99) forms spherical
particles with an immature lattice, which was shown over 15 years ago [7]. However, under
the conditions used initially, full-length Gag, which contains an intact (but not myristoylated)
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MA domain, forms only aberrant small spherical particles in vitro [2]. This size defect could be
corrected by the addition of a small amount of a rabbit reticulocyte extract to the assembly reaction.
The active ingredient in the extract was identified as inositol pentakisphosphate or IP5 [8] with inositol
hexakisphosphate (IP6 or phytic acid) later shown to be equally active. IP6 is found in mammalian
cells at concentrations in the range between 12 to 100 µM and is the most abundant of the several
multiphosphorylated inositols [9]. The biosynthetic pathway leading to this metabolite is complex and
proceeds via a phosphorylation cascade from IP3 [10].
How these inositol phosphate compounds function to correct immature assembly was the
topic of several earlier studies. One used a foot printing technique to demonstrate that in vitro IP6
interacts with multiple Lys residues in Gag with the strongest being in the MA and NC domains [11].
A subsequent study showed that IP6 could induce assembly of Gag in the absence of nucleic acid
when the NC domain was replaced with a Leucine Zipper domain, which is a construct that forms
VLPs in vivo [12]. HIV-1 MA interacts with the plasma membrane (PM) through hydrophobic and
electrostatic interactions. In particular, MA interacts specifically with the phospholipid PI(4,5)P2 [13,14].
This minor phospholipid is required for effective Gag targeting to the PM for assembly and
budding [15,16]. As a purified protein, HIV-1 Gag adopts a horseshoe-like conformation with the
N-terminal MA domain in proximity to the C-terminal NC domain [17,18]. IP6 was found to induce
Gag to take on an elongated, assembly-competent conformation [19]. Taken together, these several
observations suggested that IP6 acts on the MA domain of Gag.
In a recent paper, Dick et al. provided molecular evidence for the mechanism of IP6 action in
promoting immature assembly [20]. They showed first that the MA domain is not required for this
effect. The protein CA-SP-NC assembles inefficiently and yields mature tubes and immature spheres.
However, in the presence of physiological concentrations of IP6, CA-SP-NC assembly is increased by
as much as 100-fold with the major product being immature spherical VLPs. Thus, IP6 must bind
either to the CA, SP, or NC domains. To further delineate the site of interaction, the ability of IP6 to
promote assembly of CA-SP was tested. Remarkably, IP6 also causes this highly truncated Gag protein
to form immature VLPs, ruling out the NC domain as the primary site of action. Our findings do not
rule out that IP6 interaction with MA and NC plays a role in Gag assembly.
A feature of Gag that plays a key role in immature assembly is a stretch of 14 amino acids spanning
the CACTD and SP interface (Figure 1A). This region, SP1, forms a six-helix bundle (6HB) that stabilizes
immature Gag hexamers [21,22] and is required for immature lattice formation [7]. The six negatively
charged phosphate groups of IP6 roughly define a ring of diameter ~10 Å. Since a Gag hexamer is
the basic building block of the immature lattice, Dick et al. reasoned that a ring of positively charged
residues within the Gag hexamer could create a binding pocket with an arginine (R) or lysine (K) side
chain contacting each phosphate. Furthermore, a 4.5 Å cryo-EM structure of immature HIV-1 virus
particles [22] as well as a 3.27 Å crystal structure of a CACTD-SP hexamer [21] show two K residues,
K290 at the bottom of the CACTD hexamer and K359, near the top of the 6HB. Although the side-chains
are not visible in these structures, each lysine could potentially form a ring with the diameter of a size
that could accommodate an IP6 molecule. These two rings would be stacked roughly on top of each
other and in a cryo-EM structure obtained from enveloped immature virus particles that budded from
cells, an undefined density feature of the correct size for IP6 is observed between and inside the two
positively charged rings [22]. Lastly, hexacarboxybenzene, which is a compound structurally similar
to IP6 with six negatively charged groups, was previously shown to bind to an analogous ring of
positively charged residues at the center of the mature CA hexamers [23].
Consistent with the hypothesis that a ring of charged residues in the CACTD-SP binds IP6, IP6 was
shown to promote formation of microcrystals by this construct with the crystals having a hexameric
lattice, which was observed by 2D cryo-EM [20]. Higher resolution X-ray crystallography of these
crystals directly demonstrated that IP6 sits in a pocket formed by the two rings of six K residues
with direct interactions between the IP6 phosphates and the side chains of both K290 and K359
(Figure 2A). All-atom molecular dynamic simulations of CACTD-SP with and without IP6 further
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support the conclusion that IP6 acts to stabilize the six-helix bundle. Other inositol derivatives and
hexacarboxybenzene also stabilize the 6HB in this computational model, which is consistent with their
stimulation of immature assembly in vitro. Most importantly, mutation of either of K290 or K359 to
alanine results in a dramatic decrease in the efficiency of in vitro assembly.
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Figure 2. Immature and mature HIV capsid hexamers in complex with IP6. (A) Immature hexamer
with location of the two lysine rings indicated by side-chains and blue spheres. Numbering is given
for Gag with CA in parenthesis. Based on PDB 6BHR. The left-hand panel is annotated so that the
lysine side chains belonging to K290 are immediately below the K290 label while those belonging to
K359 are immediately above the K359 label. In the right-hand panel, the inner ring of blue spheres
corresponds to lysines at position K359 while the outer ring of blue spheres corresponds to lysines at
position K290. (B) Mature hexamer with R18 ring indicated by yellow side chains and blue spheres.
Two R18 rotamer conformers are shown. Based on PDB 6ES8. In each side-view, one monomer has
been omitted for clarity.
Does IP6 function in living cells to promote HIV-1 Gag assembly? Dick et al. using media collected
from virus-producing cells transfected with K290A or K359A plasmids observed no infections [20].
CRISPR/Cas9-mediated knockout of inositol-pentakisphosphate 2-kinase (IPPK), which is an enzyme
involved in the biosynthesis of IP6, led to more than a 10-fold decrease in HIV-1 infections [20].
These results are consistent with a role for IP6 in either viral production or infection. A prediction
of the hypothesis that IP6 promotes physiological HIV-1 immature assembly is that IP6 will be
incorporated into infectious viral particles. Virion incorporation experiments have previously been
used to show packaging of important cofactors (e.g., cyclophilin A [24]) and antiviral restriction factors
(e.g., APOBEC3G [25]). By producing HIV-1 in cells supplemented with tritiated inositol, Mallery et al.
demonstrated that IP6 is incorporated into the virus at a level of about 300 molecules per virion [26].
IP6 is selectively enriched over IP4 and IP5, which suggests that, while other inositol derivatives
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can promote assembly in vitro, IP6 is the physiologically relevant molecule. The 300 molecules of
IP6 are sufficient for most but not all of the immature hexamers in an HIV-1 virus particle based
on the estimated stoichiometry of roughly 2500 Gag molecules per virus particle depending on the
level of incompleteness of the Gag shell [27]. Qualitatively, this is consistent with the finding that
a substoichiometric ratio of IP6 to hexamer is sufficient to promote efficient in vitro assembly.
3. Maturation
HIV-1 virions that have budded from cells undergo maturation. During this step, the viral protease
cuts Gag in several places including in the 6HB, which likely disrupts the immature lattice and allows
the dissociation of IP6. The resulting CA protein then assembles into the mature conical capsid core.
Previous work had demonstrated that, at the center of each mature capsid hexamer, is a ring of six
arginine residues (R18) that avidly binds polyanions including the IP6-like hexacarboxybenzene [23].
More recent X-ray structures confirm that the R18 ring in the mature hexamer can also bind IP6 [20,26]
(Figure 2B). Evidence from cryo-EM tomographic analysis also suggests that a small molecule is bound
at this site in mature virions [28]. It is, therefore, an attractive hypothesis that IP6 might drive assembly
of the mature capsid inside virions in a similar manner to immature lattice formation. Supporting this
hypothesis, Dick et al. demonstrated that IP6 promotes the assembly of recombinant CA protein into
a mature lattice. As described above, it is only at unphysiologically high ionic strength that HIV-1 CA
had been observed to form tubular and some conical structures in vitro. The lattice of these products
is representative of the lattice of cores in budding virus particles from cells [28]. However, the addition
of IP6 to a CA assembly reaction at physiological ionic strength results in massive and unprecedented
formation of core-like structures, which predominate over tubes.
Establishing the physiological importance of IP6 in maturation is likely to be challenging.
The capsid mutation R18A ablates HIV infectivity but does not prevent mature capsids from
forming. Actually, they have been described as morphologically indistinguishable from their wild-type
counterparts [29]. Moreover, R18A partially rescues the TRIM5 restriction of the wild-type virus
during co-infection experiments, which provides functional evidence that it is correctly assembled.
However, the mutant R18A virus fails to carry out any measurable DNA synthesis during infection,
which suggests that it is unstable.
3.1. Post-Entry Infection
Post-entry infection occurs after fusion of the viral envelope with the target cell membrane
and refers to the processes that occur between cytosolic deposition of the capsid and uncoating.
Plausibly, the mature capsid has evolved to facilitate this step. It takes HIV-1 at least several hours
to establish a productive infection of the cell and reverse transcription kinetics suggest that DNA
synthesis peaks after approximately 8 to 10 h in cell lines [30–32]. In primary cells, reverse transcription
kinetics may be even slower due to the limited pool of dNTPs resulting from SAMHD1 activity.
Studies suggest a close relationship between SAMHD1, the viral antagonist Vpx, dNTP levels, and
reverse transcription kinetics in macrophages [33]. Whether reverse transcription is completed before
or after uncoating is unclear. Yet, it seems unlikely for uncoating to occur pre-strand transfer since
this would dilute both the RT enzyme and the template RNA in the cytosol, which reduces catalytic
efficiency. Moreover, early uncoating would risk exposing viral RNA and DNA to nucleic acid sensors
such as RIG-I and cGAS, which can trigger a potent antiviral response [34]. Reverse transcription can
occur in purified HIV-1 capsid cores where the enzyme and the template are at high local concentrations
and viral nucleic acid is protected [23]. However, for the encapsidated RT enzyme to synthesize DNA,
precursor dNTPs from the cytosol need to be able to access the capsid interior. In the initial description
of the charged R18 hexamer ring and its ability to bind polyanions like dNTPs and hexacarboxybenzene,
it was proposed that this feature might comprise a pore for nucleotide import [23]. However, structures
of dNTP and ATP bound to HIV-1 capsid hexamers have shown that the interactions are driven by salt
bridges, which do not provide a mechanism to discriminate between ribo-NTPs and the much less
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abundant deoxyribo-NTPs in the cytoplasm. If transport into the capsid is rate limiting, one might
expect ATP to competitively inhibit dNTP entry. In fact, addition of ATP to isolated mature capsids
increases reverse transcription rather than decreasing it [26]. It was postulated that ATP binding to the
R18 pore was preventing uncoating, which suggests that polyanions might be used by the capsid as
stabilizing cofactors.
IP6 greatly increases the thermostability of mature capsid hexamers by almost 10 ◦C [26].
Importantly, this stabilization is not due only to neutralization of the R18 charges since hexamers
made with the R18G mutant protein are less stable than wildtype hexamers in the presence of IP6.
These observations suggest that IP6 binding actually helps hold mature CA hexamers together.
The estimated 300 IP6 molecules that are packaged per virion would be sufficient for each of the
estimated 1800 CA molecules in the mature lattice to interact with IP6 [26]. Increased capsid stability
may be of particular importance during reverse transcription. The addition of IP6 to isolated capsids
potently increases viral DNA synthesis. Currently, no cellular data address the importance of IP6
in target cells while in vitro experiments suggest that IP6 stabilizes native HIV capsid cores on
a physiologically meaningful time scale. Single molecule measurements have been made on individual
GFP-containing HIV virions that are anchored to cover slips and permeabilized with a pore-forming
toxin. In this assay, HIV-1 capsids have a lifetime of ~7 min, but, in the presence of IP6, they can remain
intact and stable for more than 10 hours [26,35]. This result is particularly significant given the time it
takes for HIV to reach the nucleus and complete RT. It suggests that, without IP6, the HIV-1 capsid is
not stable for long enough to be infectious.
Which of the two possible functions for the R18 ring in post-entry HIV infection—nucleotide
import and IP6-mediated capsid stabilization—is most important remains to be determined.
The excellent correlation between loss of dNTP binding, reverse transcription, and infection when
R18 was dose-dependently replaced by glycine initially suggested that dNTPs are imported through
the pore to promote DNA synthesis [23]. However, as we now know that IP6 also binds to the R18
pore and increases the accumulation of viral DNA by stabilizing the capsid, this phenotype could be
explained by a loss of IP6 interaction. A further complication is that it seems unlikely that each pore
can accommodate more than one polyanion. Thus, a pore occupied by IP6 may be unable to act as
a conduit for dNTPs. Moreover, IP6 is already present within the virion and coordinates the R18 ring
more efficiently than dNTP and with likely a much slower off-rate. Nevertheless, there are hundreds of
pores and it may be that import of dNTPs through only a few pores at a time is sufficient. Furthermore,
if R18 pores are not involved in dNTP entry, then the question remains how nucleotides are imported
to fuel DNA synthesis. It is possible that dNTPs slip between gaps in the capsid lattice, but tests of this
idea currently are not available.
3.2. Uncoating
Exactly when (and where) uncoating occurs is controversial, but the capsid probably remains
largely intact at least until the virus reaches the nuclear pore since interaction with the nuclear pore
protein Nup153 requires mature hexamers [36]. At the same time, the capsid must be capable of rapid
uncoating, which means that it must be structurally metastable. Using a small molecule cofactor like IP6
could enable HIV to switch its capsid from a very stable to a very unstable state simply by controlling
IP6 binding. Remarkably, precedence for such a mechanism exists in virology. Picornaviruses use
small molecule cofactors called pocket factors to regulate stability of their capsid [37]. These pocket
factors are displaced during infection to facilitate uncoating [38].
If IP6 is an HIV-1 pocket factor, then how is its release controlled to trigger capsid uncoating?
An attractive hypothesis is that cellular cofactors mediate uncoating, which could ensure that the
virus uncoats in the right place at the right time and that capsid protection is lost only when it is
no longer needed. For instance, uncoating may take place at the nuclear pore, which is the case for
many nuclear DNA viruses such as adenoviruses [39] and herpes viruses [40]. Consistent with such an
idea, the HIV-1 capsid interacts with several nuclear pore proteins and associated cofactors including
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Nup153, Nup358, and CPSF6 [36,41–46]. The relevant binding interfaces are localized close to each
other in mature hexamers (Figure 3). It is plausible that allosteric pathways connect the various sites,
which allows for a cofactor interaction to influence IP6 binding. One possible mechanism for how
this might take place is if the cofactor interaction influences the orientation of the β-hairpin at the
N-terminus of CA. When the β-hairpin adopts its closed conformation, IP6 is effectively trapped in an
enclosed chamber inside the hexamer. However, when the β-hairpin is open, it becomes possible for
IP6 to dissociate away from the capsid. There is, as of yet, no direct evidence for allostery in the HIV
capsid but viral phenotypes are suggestive. For instance, CypA-binding loop mutants G89V and P90A
are partially resistant to capsid inhibitor PF74 despite not impacting PF74 binding [47]. Capsid mutant
E45A is also resistant to PF74 without preventing interaction and this residue is located proximal to the
hydrogen bond network that determines the β-hairpin orientation. Moreover, E45A has a hyper-stable
capsid phenotype, which could be explained by a model of increased β-hairpin closure and IP6
retention [48]. While we know that IP6 is packaged into virions before CA hexamer assembly and
before the capsid is deposited into a target cell, it is not clear how efficiently IP6 or other polyanions
can exchange in and out through the pore post-entry. Importantly, single molecule measurements
suggest that, while hexacarboxybenzene and IP6 greatly stabilize the capsid, once uncoating has begun,
the entire lattice quickly falls apart [35]. In contrast, while PF74 induces capsid opening—possibly by
causing pentamer release [49]—it locks the lattice together. This suggests that a partially uncoated
state is unlikely to persist since IP6 cannot be retained in a hexamer that has begun to lose subunits.
It also indicates that, while IP6 loss may be the underlying mechanism that drives rapid uncoating,
a small break in the capsid lattice or local conformational change may be sufficient to precipitate
a chain-reaction. Thus, it may not be necessary to trigger the simultaneous release of IP6 across the
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Another model that might explain loss of IP6 from the capsid is based on the ability of IP6 to
strongly chelate divalent metals. The roughly millimolar concentration of Mg++ in the cytosol might
lead to loss of IP6 due to its higher affinity for Mg++. Evaluation of this model would require the
measurement of the affinity for the CA hexamer when assembled into a mature closed capsid.
4. Conclusions
Recent data suggest that IP6 has a key role in several stages of the HIV-1 lifecycle from assembly
to uncoating. The following is a mechanistic working model for IP6 function. IP6 is recruited
into assembling virions prior to budding where it promotes formation of the immature lattice by
coordinating two rings of six lysine residues in Gag, K290 and K359. During maturation, viral protease
severs CA from SP1, which destroys the immature IP6 binding site. Liberated IP6 drives assembly of
mature hexamers by coordinating six R18 residues and facilitating formation of a metastable capsid
structure. Upon infection, capsids are deposited into the cytosol where IP6 maintains capsid integrity
during reverse transcription and transit to the nucleus. Environmental cues such as cofactor binding
or DNA accumulation induce a rapid cascade of IP6 dissociation, which leads to lattice disassembly.
Many questions about IP6 function remain to be addressed for HIV-1 and more broadly for other
retroviruses. Do other lentiviruses and other genera of retroviruses also use IP6 to modulate Gag
and CA lattice stability? If not, how are their immature and mature lattices stabilized? Does IP6
play a role in replication of the many other viruses whose structures are based on protein hexamers?
Do dNTPs enter the capsid through the R18 pore? Does IP6 in some way control the specificity for
dNTPs? Does protein cofactor binding to the HIV-1 capsid lead to the release of IP6, as suggested by
the model above? If so, what cofactor proteins play this role? The interplay of IP6 and viral structural
proteins is likely to remain a fertile ground for investigation.
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